Edding Genor Group Holdings Ltd (hkse:06998) Share Price

Company Profile

Business description
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
Contact
No. 36 Doukou Road
Room 406, Building 1
Hengqin New Area
Guangdong Province
Zhuhai
CHN
https://www.eddingpharm.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,545

Recommended

Corning’s optical fiber business is thriving, and the Meta deal derisks its supply buildout, but success isn’t guaranteed.

Ananya Chag | 27 April 2026

From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.

Malik Ahmed Khan, CFA | 24 April 2026

Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.

Mark Taylor | 24 April 2026

Index	Last price	Change	% Change
All Ordinaries	8,990.80	20.60	0.23%
CAC 40	8,141.92	15.90	-0.19%
DAX 40	24,083.53	45.45	-0.19%
Dow JONES (US)	49,167.79	62.92	-0.13%
FTSE 100	10,321.09	57.99	-0.56%
HKSE	25,925.65	52.42	-0.20%
NASDAQ	24,887.10	50.50	0.20%
Nikkei 225	60,537.36	821.18	1.38%
NZX 50 Index	12,853.51	21.43	-0.17%
S&P 500	7,173.91	8.83	0.12%
S&P/ASX 200	8,766.40	17.20	0.20%
SSE Composite Index	4,086.34	6.44	0.16%